The content is available as a PDF (95.5 KB).
Footnotes
Acknowledgments and disclosures
Acknowledgments: none. Funding sources: none. Conflicts of interest: none.
References
- 1.Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21:307–11. doi: 10.1007/s40257-020-00514-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Blaszczak A, Trinidad JCL, Cartron AM. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. J Am Acad Dermatol. 2020;83:e31. doi: 10.1016/j.jaad.2020.04.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hydradenitis suppurativa. N Engl J Med. 2016;375:422–34. doi: 10.1056/NEJMoa1504370. [DOI] [PubMed] [Google Scholar]
- 4.Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. J Dermatolog Treat 2020. doi: 10.1080/09546634.2020.1769828. [DOI] [PubMed]
- 5.Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in hydradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol 2020. doi: 10.1111/bjd.18983. [DOI] [PubMed]
- 6.Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401–9. doi: 10.1111/bjd.15748. [DOI] [PubMed] [Google Scholar]